A new settlement is reached in the Purdue Pharma opioid lawsuit; the US Surgeon General sets out to tackle online health misinformation; Florida poised to enact the state's strictest abortion ban yet.
Purdue Pharma and its owners the Sackler family have reached a $6 billion deal with 9 state attorneys general, up from a previous settlement of $4.5 billion, NPR reports. Purdue Pharma is the maker of OxyContin, an opioid that helped fuel the overdose epidemic in the United States in recent years. The states with the highest overdose death rates in the country, including Oregon, Vermont, and Washington, were among those that demanded more money from the settlement. In a statement, the Sacklers voiced regret but still denied any wrongdoing, while critics have long accused the family of aggressive opioid marketing.
The office of Surgeon General Vivek Murthy, MD, issued a request seeking data from tech companies, health care providers, and community organizations surrounding health misinformation, according to CNN. It is the first time the administration has called on the tech companies to share certain information, including data on major sources of misinformation and who may have been targeted by campaigns, publicly. Murthy has said he wants tech companies to be more transparent and open about sharing data with the public and that the initiative will help researchers better study the impact of misinformation on social platforms.
Lawmakers in Florida have approved the state’s strictest abortion ban yet, which includes no exceptions for victims of rape, incest, or human trafficking, POLITICO reports. Under the measure, which is expected to go into effect on July 1, women will be prohibited from receiving abortions after 15 weeks of pregnancy. Currently, Florida law dictates a woman cannot receive the procedure after 24 weeks of pregnancy. The move comes as states around the country are considering codifying a 15-week ban into law. The Florida law is modeled on a similar one in Mississippi.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More